HIV Genotyping NA Tests in UK

Summary

This is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective. Hospital and private laboratories have been surveyed to collect information on NA tests performed, test volumes and used platforms and reagents. For data reliability and accurate projections at segment level a 3 step methodology has been applied:

Step 1: Identification of the total number of laboratories by secondary research and short telephone interviews with 561 hospitals to verify existence of internal laboratories.

Step 2: 355 laboratories in UK were classified for NAT activity and overall NA test volume.

Step 3: 36 laboratories provided data on NA test volume, kits, platforms and trends. A list of 44 NA tests have been provided to the labs for structured data entry. All data has been analysed and projected at total market level. The report discusses tests and technologies that are currently available and wishes from the end user perspectives. The report covers key platforms of molecular diagnostics, including Polymerase Chain Reaction (PCR), Real Time PCR (RT-PCR), TMA, LCR, NASBA, SDA, HCA, bDNA.

dii is an international marketing consulting company entirely specialised in healthcare markets providing market information and support to strategic market decisions. In cooperation with key industry a Continuous European Molecular Market Assessment has been realized in 2009 with the 2 main objectives:

1) Classification of laboratories by ownership, size and overall NA test volume

2) Market assessment for 44 NA tests on volumes, trends, kits and analyzers. All data is presented in Excel and PPT. Excel addresses all quantitative questions at segment level, including all volume projection scenarios and statsitical detail, PPT presents the key data and provides an interpretation of general business implications

Contents

• Total number of clinical diagnostic labs by lab type
  • small
  • medium
  • large hospitals
  • non hospital (private) labs
• Number of clinical diagnostic NA labs by lab type
  • small
  • medium
  • large hospitals
  • non hospital (private) labs,
• By NA test volume: >/< 20 NA tests per day
• Number of lab performing test by test types
  • Adenovirus,
  • BK
  • C. Diff
  • CF
  • CMV
  • CMV Viral
  • CT
  • CT/NG
  • EBV
  • EBV Viral
  • Enterovirus
  • Factor II
  • Factor V Leiden
  • Fragile X
  • GAS
  • GBS
  • HBV qual
  • HBV resistance
  • HBV Viral Load
  • HCV Genotyping
  • HCV qual
  • HCV Viral Load
  • Her2Neu
  • HIV Genotyping
  • HIV qual
  • HIV Viral Load
  • HLA Typing
  • HPV
  • HPV Genotyping
  • HSV 1
  • HSV 2
  • Human Metapneumovirus
  • Influenza A
  • B
  • MAC (formerly MAI)
  • MRSA
  • MSSA
  • MTB
  • MTD (Tuberculosis)
  • NG
  • Parainfluenza 1, 2, 3
  • RSV
  • Staphylococcus aureus
  • VRE
  • VZV
  • Warfarin sensitivity (CYP2C9, VKOR1)
• Total Number of test/results per test type & growth rate
  • Adenovirus
  • BK
  • C. Diff
  • CF
  • CMV
  • CMV Viral
  • CT
  • CT/NG
  • EBV
  • EBV Viral
  • Enterovirus
  • Factor II
  • Factor V Leiden
  • Fragile X
  • GAS
  • GBS
  • HBV qual
  • HBV resistance
  • HBV Viral Load
  • HCV Genotyping
  • HCV qual
  • HCV Viral Load
  • Her2Neu
  • HIV Genotyping
  • HIV qual
  • HIV Viral Load
  • HLA Typing
  • HPV
  • HPV Genotyping
  • HSV 1
  • HSV 2
  • Human Metapneumovirus
  • Influenza A,B
  • MAC (formerly MAI)
  • MRSA
  • MSSA
  • MTB
  • MTD (Tuberculosis)
  • NG
  • Parainfluenza 1,2,3
  • RSV
  • Staphylococcus aureus
  • VRE
  • VZV
  • Warfarin sensitivity (CYP2C9, VKOR1)
• Market share: Number of tests/results by supplier
  • Roche Diagnostics
  • Innogenetics
  • Abbott
  • Bio-Rad
  • bioMrieux
  • Stratagene
  • Applied Biosystems
  • Qiagen
  • Siemens
  • Cepheid
  • Digene
• Installed base of analyzers
• Trends